Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4251078 | 0.91 | ALDH1A1 (0.51) | TSHRPOLBSMN1; SMN2MAPTRAB9A | |
| SCHEMBL4251152 | 0.89 | LMNA (0.52) | TSHRSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL4247717 | 0.89 | SMN1; SMN2 (0.47) | TSHRSMN1; SMN2MAPTALDH1A1MAPK1 | |
| SCHEMBL4253898 | 0.87 | SMN1; SMN2 (0.44) | TSHRSMN1; SMN2MAPTALDH1A1MAPK1 | |
| SCHEMBL4247922 | 0.86 | KMT2A (0.45) | TSHRPOLBSMN1; SMN2MAPTRAB9A | |
| SCHEMBL4252054 | 0.85 | HPGD (0.49) | TSHRPOLBSMN1; SMN2MAPTNPC1 | |
| SCHEMBL4255454 | 0.84 | TAAR1 (0.55) | POLBSMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL4255336 | 0.82 | EPHX2 (0.44) | POLBSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL4254104 | 0.72 | KDM4E (0.47) | TSHRPOLBSMN1; SMN2MAPTTP53 | |
| SCHEMBL4252127 | 0.72 | KDM4E (0.47) | TSHRPOLBSMN1; SMN2MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | TSHR 289/4885POLB 4586/4885SMN1; SMN2 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.